DK172052B1 - Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor - Google Patents

Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor Download PDF

Info

Publication number
DK172052B1
DK172052B1 DK586685A DK586685A DK172052B1 DK 172052 B1 DK172052 B1 DK 172052B1 DK 586685 A DK586685 A DK 586685A DK 586685 A DK586685 A DK 586685A DK 172052 B1 DK172052 B1 DK 172052B1
Authority
DK
Denmark
Prior art keywords
gif
ser
leu
gin
glu
Prior art date
Application number
DK586685A
Other languages
Danish (da)
English (en)
Other versions
DK586685A (da
DK586685D0 (da
Inventor
Kiyoshi Ishii
Yasuo Yanagihara
Yoshikatsu Hirai
Satoru Nakai
Mayumi Kaneta
Kazuyoshi Kawai
Yoshikazu Kikumoto
Yeong-Man Hong
Setsuko Takegata
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP60283238A external-priority patent/JPS62142121A/ja
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of DK586685D0 publication Critical patent/DK586685D0/da
Publication of DK586685A publication Critical patent/DK586685A/da
Application granted granted Critical
Publication of DK172052B1 publication Critical patent/DK172052B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK586685A 1984-12-21 1985-12-17 Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor DK172052B1 (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP27120784 1984-12-21
JP27120784 1984-12-21
JP13828185 1985-06-24
JP13828085 1985-06-24
JP13828185 1985-06-24
JP13828085 1985-06-24
JP22088285 1985-10-03
JP22088285 1985-10-03
JP28323885 1985-12-16
JP60283238A JPS62142121A (ja) 1985-12-16 1985-12-16 抗腫瘍活性物質

Publications (3)

Publication Number Publication Date
DK586685D0 DK586685D0 (da) 1985-12-17
DK586685A DK586685A (da) 1986-06-22
DK172052B1 true DK172052B1 (da) 1997-09-29

Family

ID=27527509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK586685A DK172052B1 (da) 1984-12-21 1985-12-17 Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor

Country Status (5)

Country Link
US (1) US4898818A (ko)
EP (1) EP0187991B1 (ko)
KR (1) KR930012106B1 (ko)
DE (2) DE3586050D1 (ko)
DK (1) DK172052B1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998578A (en) * 1984-05-18 1999-12-07 New England Medical Center Hospitals, Inc. Biologically active fragments of IL-1β
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
IE61353B1 (en) * 1984-06-19 1994-11-02 Immunex Corp Purified interleukin 1
JP2583770B2 (ja) 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5047505A (en) * 1987-01-27 1991-09-10 Du Pont Merck Pharmaceutical Company High level expression in E. coli of soluble mature HIL-1beta and derivatives with altered biological activity
KR960008010B1 (ko) * 1988-07-29 1996-06-19 오오쓰까세이야꾸 가부시끼가이샤 IL-1α 유도체 및 혈소판 감소증 치료 약제
FR2636231A1 (fr) * 1988-09-09 1990-03-16 Sanofi Sa Cellules eucaryotes recombinees productrices d'interleukine-1 (beta) mature n-glycosylee, procede et vecteurs necessaires pour leur obtention et procede d'obtention d'interleukine-1 (beta) mature n-glycosylee
DE68925935T2 (de) * 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
US5649904A (en) * 1988-10-07 1997-07-22 Sandoz Ltd. Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both
DE3907244A1 (de) * 1989-03-07 1990-09-13 Knoll Ag Erzeugnisse, enthaltend ein lithiumsalz und einen tumor-nekrose-faktor
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US5849282A (en) * 1990-05-09 1998-12-15 Otsuka Pharmaceutical Co., Ltd. Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
US5723117A (en) * 1990-08-10 1998-03-03 Otsuka Pharmaceutical Co., Ltd. Use of interleukin-1 (IL-1) to inhibit development of hepatitis
US6446032B1 (en) * 1990-09-21 2002-09-03 Massachusetts Institute Of Technology Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove
GB9112553D0 (en) * 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US7276335B1 (en) * 1993-09-29 2007-10-02 Massachusetts Institute Of Technology Designing compounds specifically inhibiting ribonucleic acid function
US6120770A (en) * 1997-09-12 2000-09-19 University Of Notre Dame Du Lac Plasmodium proteins useful for preparing vaccine compositions
GB9916630D0 (en) * 1999-07-16 1999-09-15 Univ Manchester Molecules derived from interleukins
GB0525866D0 (en) * 2005-12-20 2006-02-01 Cambridge Microbial Technologi Chemical induction of quiescence in cells
MX360097B (es) 2010-07-29 2018-10-22 Eleven Biotherapeutics Inc Agonistas y antagonistas del receptor tipo i de il-1 quimérico.
WO2014160371A1 (en) 2013-03-13 2014-10-02 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
FR2550802B1 (fr) * 1983-08-17 1986-04-11 Inst Nat Sante Rech Med Procede de production d'interleukine 1 humaine et medicaments correspondants
JPS60149386A (ja) * 1984-01-17 1985-08-06 Dainippon Pharmaceut Co Ltd インタ−ロイキン１をコ−ドする伝令リボ核酸及びその調製法
CA1341401C (en) * 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
EP0155433A1 (en) * 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
DE3588241T2 (de) * 1984-05-18 2002-12-05 New England Medical Center Inc Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
IE61353B1 (en) * 1984-06-19 1994-11-02 Immunex Corp Purified interleukin 1
EP0188920B1 (en) * 1984-12-25 1993-09-29 Dainippon Pharmaceutical Co., Ltd. Interleukin 1 and its derivative
AU577856B2 (en) * 1985-01-17 1988-10-06 Immunex Corporation Cloning and characterization of the human interleukin 1 gene
DE3683186D1 (de) * 1985-04-25 1992-02-13 Hoffmann La Roche Rekombinantes humaninterleukin-1.

Also Published As

Publication number Publication date
EP0187991A3 (en) 1988-03-16
DE3586050D1 (ko) 1992-06-17
US4898818A (en) 1990-02-06
DK586685A (da) 1986-06-22
EP0187991B1 (en) 1992-05-13
KR860005022A (ko) 1986-07-16
KR930012106B1 (ko) 1993-12-24
DK586685D0 (da) 1985-12-17
EP0187991A2 (en) 1986-07-23
DE187991T1 (de) 1987-04-30

Similar Documents

Publication Publication Date Title
DK172052B1 (da) Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
KR910009900B1 (ko) 생물학적 활성 단백질의 합성 뮤테인 및 이의 제조방법
EP0118617B1 (en) Interleukin-2 polypeptides
USRE33653E (en) Human recombinant interleukin-2 muteins
DK171647B1 (da) Polypeptid, der er et interleukin-1 alfa-derivat, gen, der koder for polypeptidet, vektor indeholde nde genet, mikroorganisme indeholdende vektoren, og lægemiddel indeholdende polypeptidet
EP0237967B1 (en) IL-1 beta derivatives and drugs
EP0098862A1 (en) Interferon-alpha 76
EP0099389A1 (en) Interferon-alpha 54
EP0413818B1 (en) Process for producing a human neutrophil chemotactic factor polypeptide
EP0098864A1 (en) Interferon-alpha 74
HU202922B (en) Process for producing new limphotoxin-polypeptides
US5847098A (en) DNA encoding interleukin IL-1β mutant
EP0218431B1 (en) Novel polypeptides, dnas that code for the same and method of preparing said polypeptides and dnas
US6107465A (en) IL-1β and derivatives thereof and drugs
AU601173B2 (en) Il-beta derivatives and drugs
EP0327360B1 (en) Novel polypeptides and DNA encoding said polypeptides
JP2753694B2 (ja) インターロイキン−１β誘導体及び医薬
JP2583753B2 (ja) 抗腫瘍活性物質およびその製造法
JP2721854B2 (ja) 抗腫瘍活性物質
JP2608023B2 (ja) インターロイキン−１β誘導体及び医薬
JPS62142121A (ja) 抗腫瘍活性物質
JPH06219964A (ja) 抗腫瘍剤
JPH1072365A (ja) 医薬製剤
JPH06220093A (ja) インターロイキン−１α誘導体
JPH08253422A (ja) インターロイキン−１β誘導体及び医薬

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed